Primary and lasting benefits in pregnancy.
While updating my database of human clinical trials using expanded human umbilical cord mesenchymal cells I came across a new article (April, 2016) describing a 36-month safety in subjects given intravenous cells for in a type 2 diabetes study. The study, a phase I/II, 36‑month, randomized controlled trial was conducted in patients diagnosed with T2DM according to the criteria outlined by the American Diabetes Association and performed at Qingdao University by Dr. Jianxia Hu et. al. 1 Not only were there no adverse events in the treatment group of 31 subjects but there were significant improvements in blood sugar control and decreased diabetes-related complications.
Two intravenous infusions of expanded human umbilical cord mesenchymal stem cells were given four weeks apart. The dose of each infusion was based on the weight of the subjects and averaged 60 million cells.
Significant improvements were seen in post-prandial glucose and hemoglobin A-1C levels but not fasting glucose. C-peptide (surrogate for endogenous insulin production) and C-peptide to glucose ratio were both significantly improved in the treatment group. Significant improvement was seen in the HOMA‑β, homeostasis model assessment of pancreatic islet β‑cell function; while there was no improvement in the HOMA‑IR, homeostasis model assessment of insulin resistance.
The improvements seemed to peak between 15 and 21 months after treatment supporting a rationale for re-treatment before 15 months.
Duchenne Muscular Dystrophy (DMD) is a degenerative genetic disorder that affects the muscles in the body in a progressive manner, leading to eventual death. Mesenchymal stem cells (MSC) are able to reach the affected muscle cells and to start tissue … [Continue reading]
Treatment with human umbilical cord mesenchymal stem cells is shown to be effective in controlling hypertension and reducing the infiltration of inflammatory cells in the placenta, in this preeclampsia rat model. Reprod Sci. 2016 Feb 17. … [Continue reading]
Human umbilical cord mesenchymal stem cells (hUCMSC) were found to improve liver condition in rats after acute liver failure, slowing the degeneration of liver cells. The results were comparable whether treatment was administered intravenously or via … [Continue reading]
In this new 2016 study, rats with spinal cord injury (SCI) were treated with conditioned medium or secretome obtained from human CD34 umbilical cord stem cells. Locomotor function was improved; in particular, neurological deficits, cell death, extent … [Continue reading]